
About Gujarat Themis Biosyn
Gujarat Themis Biosyn is a publicly listed company based in Vapi (India) founded in 1981. Application development services are provided from Vapi, India. The company has 224 employees. Gujarat Themis Biosyn has completed 1 acquisition, including MicroBiopharm Japan. Its chief executive, as recorded, is Tapas Bhudebendranath Guhathakurata. Its Indian entity Gujarat Themis Biosyn Ltd reported revenue of βΉ168 Cr. Gujarat Themis Biosyn offers products and services including Rifampicin. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and Jubilant Pharma; 2 of its 3 listed similar companies have raised funding.
Company details
Gujarat Themis Biosyn was established in 1981 and is headquartered in Vapi, India. Operations are centered on the information technology sector, where application development services are delivered to support software needs. The company functions within the software services industry, focusing on custom application solutions. Leadership is provided by CEO Tapas Bhudebendranath Guhathakurata, with activities conducted primarily in the Indian market.
- Market Cap₹4,676 Cr
GUJTHEM · NSE
- Share Price₹349.00
-2.85% today
- Revenue₹166 Cr
FY 2025-26 · +10.0% YoY
- EBITDA₹76.41 Cr
Margin 46.1%
- Net Profit₹46.67 Cr
FY 2025-26 · -4.3% YoY
- P/E (TTM)108.4x
P/B 6.7x
- ROE17.4%
ROCE 18.1%
- Debt / Equity0.36
Interest cover 6.0x
- Employee Count224
- Investments & Acquisitions
Associated legal entities of Gujarat Themis Biosyn
Gujarat Themis Biosyn operates through Gujarat Themis Biosyn Ltd, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Gujarat Themis Biosyn Ltd Listed CIN L24230GJ1981PLC004878 | Active | 11 Dec 1981 | Valsad, Gujarat | ₹168 Cr | 354 | 9 | View details |
Products & Services of Gujarat Themis Biosyn
Gujarat Themis Biosyn offers a comprehensive portfolio of products and services, including Rifampicin.
Antibiotic for tuberculosis treatment manufactured commercially.
Board of directors of Gujarat Themis Biosyn Ltd (Gujarat Themis Biosyn)
Gujarat Themis Biosyn Ltd is the primary company behind Gujarat Themis Biosyn. The board of Gujarat Themis Biosyn Ltd currently have 7 directors; the longest-serving is Dinesh Shantilal Patel, appointed in 1992. 28 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Dinesh Shantilal Patel DIN 00033273 | Director | 25 May 1992 | 34 yrs 5 mo | Gujarat Themis Biosyn Ltd |
| Sachin Dinesh Patel DIN 00033353 | Managing Director | 25 Oct 2008 | 18 yrs | Gujarat Themis Biosyn Ltd |
| Kirandeep Kaur Madan DIN 00686547 | Director | 01 May 2021 | 5 yrs 6 mo | Gujarat Themis Biosyn Ltd |
| Hitesh Dharmasinh Gajaria DIN 10044310 | Director | 14 May 2024 | 2 yrs 6 mo | Gujarat Themis Biosyn Ltd |
| Kumarapuram Gopalakrishnan Ananthakrishnan DIN 00019325 | Director | 26 Jul 2024 | 2 yrs 3 mo | Gujarat Themis Biosyn Ltd |
| Nihar Ajay Parikh DIN 02475787 | Director | 01 Aug 2025 | 1 yr 3 mo | Gujarat Themis Biosyn Ltd |
| Rajneesh Kedarnath Anand DIN 00134856 | Additional Director | 10 Nov 2025 | 1 yr | Gujarat Themis Biosyn Ltd |
People of Gujarat Themis Biosyn
1 people are tracked at Gujarat Themis Biosyn (1 in leadership); the tracked headcount is 224.
| Name | Role | Group |
|---|---|---|
Tapas Bhudebendranath Guhathakurata | CEO | Leadership |
Complete people profiles for Gujarat Themis Biosyn
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Gujarat Themis Biosyn
Gujarat Themis Biosyn is a publicly listed company on the NSE with ticker symbol GUJTHEM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Feb 2025
- Listed onNSE: GUJTHEM
- Listed entityGujarat Themis Biosyn Ltd
- Exchange sectorHealth technology
- ISININE942C01045
- Share price₹389.15 (+4.33% on the day) · 2026-10-14
- Market capitalisation₹4,836 Cr
- Price to earnings87.1
- EPS (diluted, trailing year)₹4.47
- Dividend yield0.18%
- Volume (last session)474,150
Financials of Gujarat Themis Biosyn
Exchange-reported figures of Gujarat Themis Biosyn Ltd, the listed company behind Gujarat Themis Biosyn (NSE: GUJTHEM).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 166 | 151 | 170 | 148 | 115 | 90.56 | 85.12 |
| Revenue growth | +10.0% | -11.2% | +14.4% | +29.2% | +26.8% | +6.4% | - |
| EBITDA | 76.41 | 68.84 | 78.72 | 73.64 | 58.05 | 40.33 | 31.84 |
| EBITDA margin | +46.1% | +45.7% | +46.4% | +49.6% | +50.5% | +44.5% | +37.4% |
| Profit before tax | 62.08 | 65.55 | 79.33 | 77.47 | 59.04 | 40.89 | 31.26 |
| Net profit | 46.67 | 48.78 | 59.15 | 57.97 | 43.63 | 30.17 | 23.05 |
| Net profit margin | +28.1% | +32.4% | +34.8% | +39.1% | +38.0% | +33.3% | +27.1% |
| EPS (βΉ) | 4.28 | 4.48 | 8.14 | 39.90 | 30.03 | 20.77 | 16.30 |
| Balance sheet | |||||||
| Total assets | 451 | 280 | 205 | 150 | 105 | 75.29 | 50.84 |
| Net worth | 288 | 248 | 201 | 149 | 103 | 69.94 | 42.19 |
| Total debt | 162 | 30.47 | 2.77 | 0.42 | 1.17 | 4.83 | 8.15 |
| Cash & bank | 6.09 | 12.55 | 8.16 | 9.33 | 12.35 | 27.64 | 2.08 |
| Net working capital | 42.74 | 32.26 | 32.95 | 46.87 | 61.98 | 51.32 | 16.75 |
| Cash flow | |||||||
| Cash from operations | 48.78 | 91.03 | 64.21 | 39.48 | 40.31 | 10.53 | 0.63 |
| Cash from investing | (172) | (112) | (55.21) | (20.41) | (29.83) | (2.25) | (2.98) |
| Cash from financing | 115 | 26.01 | (8.59) | (13.27) | (14.00) | (5.16) | 2.10 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.46 | 43.79 | 44.23 | 43.37 | 42.35 | 35.87 | 37.74 | 39.52 |
| Revenue growth (YoY) | +12.1% | +22.1% | +17.2% | +9.7% | +22.0% | -7.6% | - | - |
| Other income | 3.68 | 0.13 | 0.92 | 0.42 | 0.82 | 0.27 | 1.35 | 0.24 |
| Total expenses | 29.73 | 23.00 | 24.87 | 22.06 | 21.41 | 21.95 | 21.70 | 20.65 |
| EBITDA | 17.73 | 20.79 | 19.36 | 21.31 | 20.94 | 13.92 | 16.04 | 18.87 |
| EBITDA margin | +37.4% | +47.5% | +43.8% | +49.1% | +49.4% | +38.8% | +42.5% | +47.7% |
| Depreciation | 3.99 | 3.97 | 4.04 | 3.89 | 2.96 | 2.03 | 1.23 | 1.56 |
| Interest | 6.36 | 1.79 | 1.91 | 0.96 | 0.04 | 0.04 | 0.07 | 0.14 |
| Profit before tax | 11.06 | 15.16 | 14.33 | 16.88 | 18.76 | 12.12 | 16.09 | 17.41 |
| Tax | 2.59 | 4.10 | 3.45 | 4.41 | 4.49 | 3.06 | 4.09 | 4.43 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.46 | 43.79 | 44.23 | 43.37 | 42.35 | 35.87 | 37.74 | 39.52 |
| Revenue growth (YoY) | +12.1% | +22.1% | +17.2% | +9.7% | +22.0% | -7.6% | - | - |
| Other income | 3.68 | 0.13 | 0.92 | 0.42 | 0.82 | 0.27 | 1.35 | 0.24 |
| Total expenses | 29.73 | 23.00 | 24.87 | 22.06 | 21.41 | 21.95 | 21.70 | 20.65 |
| EBITDA | 17.73 | 20.79 | 19.36 | 21.31 | 20.94 | 13.92 | 16.04 | 18.87 |
| EBITDA margin | +37.4% | +47.5% | +43.8% | +49.1% | +49.4% | +38.8% | +42.5% | +47.7% |
| Depreciation | 3.99 | 3.97 | 4.04 | 3.89 | 2.96 | 2.03 | 1.23 | 1.56 |
| Interest | 6.36 | 1.79 | 1.91 | 0.96 | 0.04 | 0.04 | 0.07 | 0.14 |
| Profit before tax | 11.06 | 15.16 | 14.33 | 16.88 | 18.76 | 12.12 | 16.09 | 17.41 |
| Tax | 2.59 | 4.10 | 3.45 | 4.41 | 4.49 | 3.06 | 4.09 | 4.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 166 | 151 | 170 | 148 | 115 | 90.56 | 85.12 |
| Revenue growth | +10.0% | -11.2% | +14.4% | +29.2% | +26.8% | +6.4% | - |
| Other income | 2.43 | 2.44 | 4.38 | 6.59 | 4.05 | 3.27 | 1.70 |
| Total expenses | 89.41 | 81.96 | 91.10 | 74.75 | 56.80 | 50.23 | 53.28 |
| Employee cost | 14.99 | 11.44 | 10.21 | 7.75 | 7.08 | 7.11 | 6.43 |
| EBITDA | 76.41 | 68.84 | 78.72 | 73.64 | 58.05 | 40.33 | 31.84 |
| EBITDA margin | +46.1% | +45.7% | +46.4% | +49.6% | +50.5% | +44.5% | +37.4% |
| Depreciation | 12.92 | 5.37 | 3.54 | 2.58 | 2.23 | 1.73 | 1.36 |
| Interest | 3.84 | 0.36 | 0.23 | 0.18 | 0.83 | 0.98 | 0.92 |
| Profit before tax | 62.08 | 65.55 | 79.33 | 77.47 | 59.04 | 40.89 | 31.26 |
| Tax | 15.41 | 16.77 | 20.18 | 19.50 | 15.41 | 10.71 | 7.59 |
| Net profit | 46.67 | 48.78 | 59.15 | 57.97 | 43.63 | 30.17 | 23.05 |
| Net profit margin | +28.1% | +32.4% | +34.8% | +39.1% | +38.0% | +33.3% | +27.1% |
| EPS (βΉ) | 4.28 | 4.48 | 8.14 | 39.90 | 30.03 | 20.77 | 16.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.90 | 10.90 | 7.26 | 7.26 | 7.26 | 7.26 | 7.26 |
| Reserves & surplus | 277 | 237 | 194 | 142 | 96.06 | 62.68 | 34.93 |
| Shareholders' funds (net worth) | 288 | 248 | 201 | 149 | 103 | 69.94 | 42.19 |
| Secured loans | 160 | 29.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 1.95 | 0.58 | 2.77 | 0.42 | 1.17 | 4.83 | 8.15 |
| Total debt | 162 | 30.47 | 2.77 | 0.42 | 1.17 | 4.83 | 8.15 |
| Total liabilities | 451 | 280 | 205 | 150 | 105 | 75.29 | 50.84 |
| Assets | |||||||
| Gross block | 317 | 59.33 | 51.21 | 44.04 | 28.24 | 25.52 | 21.93 |
| Net block | 289 | 41.29 | 38.02 | 32.66 | 19.43 | 18.95 | 17.08 |
| Capital work in progress | 121 | 184 | 91.22 | 20.59 | 12.70 | 2.07 | 0.36 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Inventories | 15.42 | 5.05 | 3.33 | 14.62 | 11.61 | 6.05 | 6.03 |
| Sundry debtors | 60.92 | 31.24 | 27.03 | 17.91 | 25.12 | 14.71 | 20.23 |
| Cash & bank balances | 6.09 | 12.55 | 8.16 | 9.33 | 12.35 | 27.64 | 2.08 |
| Loans & advances | 6.36 | 3.14 | 9.05 | 19.87 | 29.31 | 14.92 | 0.79 |
| Total current assets | 88.79 | 51.98 | 47.57 | 61.73 | 78.39 | 63.32 | 29.13 |
| Total current liabilities | 46.05 | 19.72 | 14.62 | 14.86 | 16.41 | 12.00 | 12.38 |
| Net working capital | 42.74 | 32.26 | 32.95 | 46.87 | 61.98 | 51.32 | 16.75 |
| Total assets | 451 | 280 | 205 | 150 | 105 | 75.29 | 50.84 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 11.69 | 6.47 | 6.06 | 0.26 | 3.97 | 0.86 | 1.12 |
| Net cash from operating activities | 48.78 | 91.03 | 64.21 | 39.48 | 40.31 | 10.53 | 0.63 |
| Net cash from investing activities | (172) | (112) | (55.21) | (20.41) | (29.83) | (2.25) | (2.98) |
| Net cash from financing activities | 115 | 26.01 | (8.59) | (13.27) | (14.00) | (5.16) | 2.10 |
| Net change in cash | (8.57) | 5.22 | 0.41 | 5.79 | (3.51) | 3.12 | (0.26) |
| Closing cash | 6.09 | 12.55 | 8.16 | 9.33 | 12.35 | 27.64 | 2.08 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.0% | -11.2% | +14.4% | +29.2% | +26.8% | +6.4% | - |
| EBITDA growth | +11.0% | -12.6% | +6.9% | +26.9% | +43.9% | +26.7% | - |
| PBT growth | -5.3% | -17.4% | +2.4% | +31.2% | +44.4% | +30.8% | +282.2% |
| Net income growth | -4.3% | -17.5% | +2.0% | +32.9% | +44.6% | +30.9% | - |
| Revenue CAGR (3Y) | +3.8% | +9.5% | +23.3% | +20.4% | +40.9% | +32.7% | +33.6% |
| EBITDA CAGR (3Y) | +1.2% | +5.9% | +25.0% | +32.3% | +99.2% | +86.3% | +74.0% |
| Profitability & leverage | |||||||
| Net income margin | +28.1% | +32.4% | +34.8% | +39.1% | +38.0% | +33.3% | +27.8% |
| Return on capital employed | +18.1% | +27.2% | +44.8% | +60.9% | +66.4% | +66.4% | +84.8% |
| Return on net worth | +17.4% | +21.7% | +33.8% | +45.9% | +50.4% | +53.8% | +78.0% |
| Debt / equity | 0.36 | 0.07 | 0.01 | 0.01 | 0.03 | 0.12 | 0.23 |
| Long-term debt / equity | 0.30 | 0.07 | 0.00 | 0.00 | 0.01 | 0.04 | 0.05 |
| Interest cover | 6.05 | 0.57 | 0.31 | 0.25 | 1.49 | 2.54 | 3.02 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.88 | 2.73 | 3.57 | 4.11 | 4.27 | 3.82 | 4.25 |
| Inventory turnover | 16.20 | 35.99 | 18.92 | 11.31 | 13.01 | 14.99 | 26.73 |
| Debtors turnover | 3.60 | 5.18 | 7.56 | 6.90 | 5.77 | 5.18 | 6.54 |
| EPS (βΉ) | 4.28 | 4.48 | 8.14 | 39.90 | 30.03 | 20.77 | 16.30 |
| Dividend per share (βΉ) | 0.67 | 0.67 | 1.00 | 5.40 | 11.00 | 0.00 | 1.65 |
| Book value per share (βΉ) | 26.41 | 22.79 | 27.72 | 102.66 | 71.11 | 48.14 | 29.04 |
Investments & Acquisitions by Gujarat Themis Biosyn
Gujarat Themis Biosyn has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include MicroBiopharm Japan.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Contract research and discovery services are provided to biopharma firms. | microbiopharm.com | Tokyo, Japan | 2011 | May 2026 | β’β’β’β’ |
Complete acquisition details for Gujarat Themis Biosyn
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Gujarat Themis Biosyn
3 dated milestones of Gujarat Themis Biosyn across 45 years, from founding to its latest funding, stage changes and deals.
- Founded Gujarat Themis Biosyn is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires MicroBiopharm Japan.
Similar companies to Gujarat Themis Biosyn
Gujarat Themis Biosyn has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and Jubilant Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| jubilantpharma.com | 1978 | Noida, India | Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. |
Detailed similar companies of Gujarat Themis Biosyn
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Gujarat Themis Biosyn
The website of Gujarat Themis Biosyn (gtbl.in) receives about 3.6K visits a month.
- Monthly visits3.6K
▲ 65.3% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Gujarat Themis Biosyn (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gujarat Themis Biosyn
Complete news archive for Gujarat Themis Biosyn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gujarat Themis Biosyn
Gujarat Themis Biosyn was founded in 1981.
Gujarat Themis Biosyn is headquartered in Vapi, India. It is registered at Vapi, Gujarat, India.
Tapas Bhudebendranath Guhathakurata is the CEO of Gujarat Themis Biosyn, as recorded in our data.
Gujarat Themis Biosyn has 224 employees.
The primary company behind Gujarat Themis Biosyn, Gujarat Themis Biosyn Ltd, reported revenue of βΉ168 Cr for FY 2026, up 10% year on year.
Gujarat Themis Biosyn was established in 1981 and is headquartered in Vapi, India. Operations are centered on the information technology sector, where application development services are delivered to support software needs. The company functions within the software services industry, focusing on custom application solutions. Leadership is provided by CEO Tapas Bhudebendranath Guhathakurata, with activities conducted primarily in the Indian market.
Gujarat Themis Biosyn's top competitors include Laurus Labs, Symbiotec and Jubilant Pharma.
Gujarat Themis Biosyn offers Rifampicin.
Yes, Gujarat Themis Biosyn is publicly traded on NSE under the ticker symbol GUJTHEM.
Gujarat Themis Biosyn has made 1 acquisition, including MicroBiopharm Japan.
Gujarat Themis Biosyn operates through Gujarat Themis Biosyn Ltd.
The legal entities of Gujarat Themis Biosyn currently have 9 directors, including Dinesh Shantilal Patel, Sachin Dinesh Patel, Kirandeep Kaur Madan and others.
